Blood & Marrow Transplantation
Message From the Chief
Welcome to the Division of Blood and Marrow Transplantation. We are very proud of the outstanding compassionate care that we provide our patients along with conducting state of the art basic and translational science on stem cell biology, cellular immunology and transplantation biology.
The BMT program at Stanford performs autologous and allogeneic transplantations for over 300 patients each year. The program has been very successful with a history of limited morbidity rates and acute mortality that is well below most published reports.
Make a Gift
Our cutting-edge research is developing novel immunotherapy for cancer. Support the BMT Division by making a donation to our research fund.
In the News
A Non-Myeloablative Allogeneic Transplant Becomes the Ultimate ImmunoTherapy
While the graft-versus-cancer effect is highly desirable after allogeneic transplant, the toxicities associated with high dose chemotherapy/radiation during the conditioning regimen have been a barrier.
Precision Medicine: Applying Cutting-Edge Technology to Patient Care
One of the challenges to monitor disease status in hematologic malignancies after a curative treatment such as transplant is the lack of a patient-specific and sensitive test.
Cellular Therapeutics: Release the Power of Individual Cellular Component
While the role for the individual cell population of the donor graft is not fully understood after allogeneic transplant, recent works in the field have yielded some interesting observations which may lead to advances in clinical care.
DO YOU KNOW?
More than 360 adults have received bone marrow or stem cell transplants at Stanford every year.